To compare the effectiveness of oral tablets of tranexamic acid and vitamin C versus injections of tranexamic acid and vitamin C over face in patients with melasma

To compare the safety and efficacy of oral tranexamic acid and vitamin C with that of intralesional injection of tranexamic acid and vitamin C in patients with melasma - Nil

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/01/061709

Enrollment

100

Registered

2024-01-22

Start date

Unknown

Completion date

Unknown

Last updated

2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L818- Other specified disorders of pigmentation

Interventions

Intervention1: Group A will be given oral Tranexamic acid and Vitamin C: Oral tablet tranexamic acid in a dose of 250 mg twice daily and tablet vitamin C in a dose of 500 mg once daily will be given f

Eligibility

Inclusion criteria

Inclusion criteria: All patients of melasma presenting consecutively in the outdoor clinic of Department of Dermatology, Venerology & Leprosy of Dr. R.P.G.M.C, Kangra at Tanda, Himachal Pradesh

Exclusion criteria

Exclusion criteria: 1) Pregnant and lactating women 2) Patients taking oral contraceptives 3) Patients with prior history of thromboembolism, bleeding disorders, and abnormal coagulogram 4) Patients with psychological disorders 5) Patients with active herpetic lesions or warts on face 6) Patients having over expectation from the treatment 7) Patients who have taken any other therapy for melasma within last one month.

Design outcomes

Primary

Measure	Time frame
The modified Melasma Assessment Severity Index (mMASI) score will be the primary outcome measure.Timepoint: It will be determined at baseline before treatment and thereafter, at the end of 4, 8 and 12 weeks of treatment.	—

Secondary

Measure	Time frame
Side effects related to treatment willbe recordedTimepoint: After each visit	—

Countries

India

Contacts

Public ContactCharu Singh

Department of DVL, Dr RPGMC Tanda

hoddermatologytanda@gmail.com9418457647

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026